Merck Shareholders Reap 66.5% Gain Despite Recent Struggles

Merck's shareholders might have had a rough year considering the company's recent headlines about acquisition charges and a swing from profit to loss. However, investors who held Merck over the past year are up 66.5%, including dividends.

This gap between messy accounting results and a powerful gain is hard to ignore. To determine whether this payoff was worth the risks, investors had to weigh two different narratives about Merck's future.

The bullish narrative saw Fair Value at US$102, or 14% above the start price of US$89.51. It relied on revenue growth of 4.2%, a profit margin assumption of 33.7%, and a future P/E of 12.3x. Over 20 planned product launches and a much larger late-stage pipeline were expected to do the heavy lifting.

The more cautious view put Fair Value at US$74, or 17% below the start price. That narrative treated revenue growth of 2.8%, a 27.3% margin, and a future P/E of 12.1x as more realistic, while flagging risks around acquisitions and the impact of Keytruda's eventual patent expiry.

The Q2 2026 report was a clear event for Merck. Revenue moved from US$15,806m in Q2 2025 to US$16,607m in Q2 2026, which helped the growth assumption in the bullish case. However, profit told a different story. Net income excluding extra items turned from US$4,427m to a loss of US$1,335m and net margin shifted from 28.0% to a negative 8.0%. This profitability gap meant the evidence cut both ways.